Next Issue
Volume 88, August
Previous Issue
Volume 88, April
 
 
arm-logo

Journal Browser

Journal Browser
Advances in Respiratory Medicine is published by MDPI from Volume 90 Issue 4 (2022). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Via Medica.

Adv. Respir. Med., Volume 88, Issue 3 (July 2020) – 18 articles , Pages 173-291

  • Issues are regarded as officially published after their release is announced to the table of contents alert mailing list.
  • You may sign up for e-mail alerts to receive table of contents of newly released issues.
  • PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.
Order results
Result details
Select all
Export citation of selected articles as:
556 KiB  
Letter
Infliximab-Induced Erythema Multiforme in a Patient with Chronic Sarcoidosis
by Andreas Afthinos, Aggeliki Pandi, Maria Horti and Ilias C. Papanikolaou
Adv. Respir. Med. 2020, 88(3), 289-291; https://doi.org/10.5603/ARM.2020.0131 - 18 Jul 2020
Cited by 1 | Viewed by 395
Abstract
Tumor Necrosis Factor-α (TNF-α) inhibitors, in particular infliximab, have shown effectiveness as a third-line treatment option in relapsing, refractory sarcoidosis that requires an increased dose of corticosteroids plus one or more anti-sarcoidosis disease modifying drugs [...] Full article
1628 KiB  
Case Report
An Uncommon Presentation of Osteosarcoma
by Mantha Satya Padmaja, Sourin Bhuniya, Suprava Naik, Mukund Sable, Sudip Ghosh and Prasanta Raghab Mohapatra
Adv. Respir. Med. 2020, 88(3), 282-284; https://doi.org/10.5603/ARM.2020.0121 - 18 Jul 2020
Viewed by 318
Abstract
A 20-year old female presented to our department with complaints of sudden-onset dyspnea and right-sided chest pain for the last month [...] Full article
521 KiB  
Case Report
Unusual Initial Presentation of ABPA as Hydropneumothorax
by Juvva Kishan Srikanth, Nitesh Gupta, Sumita Agrawal, Shibdas Chakrabarti and Pranav Ish
Adv. Respir. Med. 2020, 88(3), 280-281; https://doi.org/10.5603/ARM.2020.0115 - 18 Jul 2020
Viewed by 334
Abstract
A 48-year-old female with bronchial asthma presented with right-sided pleuritic chest pain since 20 days followed by cough with expectoration and shortness of breath since 15 days [...] Full article
369 KiB  
Case Report
Antidiarrheal Pill in the Airway
by Viswesvaran Balasubramanian, Hari Kishan Gonuguntla and Nitesh Gupta
Adv. Respir. Med. 2020, 88(3), 278-279; https://doi.org/10.5603/ARM.2020.0114 - 18 Jul 2020
Cited by 1 | Viewed by 315
Abstract
Pill aspiration depicts an unusual type of foreign body aspiration necessitating a discrete diagnostic and therapeutic approach [...] Full article
562 KiB  
Case Report
Progressive Bronchiectasis and CMC in a Patient with STAT1 GOF—A Rare Case of Primary Immunodeficiency
by Hanna Dmeńska, Małgorzata Pac, Małgorzata Skomska-Pawliszak, Barbara Pietrucha, Beata Wolska-Kuśnierz, Barbara Piątosa, Justyna Komarnicka and Edyta Heropolitańska-Pliszka
Adv. Respir. Med. 2020, 88(3), 271-277; https://doi.org/10.5603/ARM.2020.0112 - 18 Jul 2020
Cited by 2 | Viewed by 367
Abstract
Bronchiestasis is a common complication developing in patients with primary immunodeficiency disorders. AD GOF STAT1 defi-ciency is characterized by CMC, repeated infections, and autoimmunity. It is the most frequently diagnosed entity in a group of PIDs with CMC. Here, we present the first [...] Read more.
Bronchiestasis is a common complication developing in patients with primary immunodeficiency disorders. AD GOF STAT1 defi-ciency is characterized by CMC, repeated infections, and autoimmunity. It is the most frequently diagnosed entity in a group of PIDs with CMC. Here, we present the first Polish case of a female patient with early-onset bronchiestasis accompanied by CMC and a severe course of infections who was genetically diagnosed with AD GOF1 STAT1 mutation at the age of 15. Full article
2396 KiB  
Case Report
Sialadenoma Papilliferum of the Bronchus: A Rare Tumour of Salivary Gland Origin
by Alessio Campisi, Andrea Dell’Amore, Luca Bertolaccini, Costantino Ricci, Alessandra Cancellieri and Franco Stella
Adv. Respir. Med. 2020, 88(3), 267-270; https://doi.org/10.5603/ARM.2020.0111 - 18 Jul 2020
Cited by 6 | Viewed by 320
Abstract
Sialadenoma papilliferum is a benign salivary tumour which rarely occurs in the bronchial tree. Up to now, only four cases of pulmonary papillary sialadenoma have been reported in the literature. We discuss the case of a male patient with an accidental finding of [...] Read more.
Sialadenoma papilliferum is a benign salivary tumour which rarely occurs in the bronchial tree. Up to now, only four cases of pulmonary papillary sialadenoma have been reported in the literature. We discuss the case of a male patient with an accidental finding of a middle lobe nodule. The patient underwent a minimally invasive anatomical resection of the lobe to remove the lesion; the postoperative course was regular, and he was healthy at the last follow-up. Full article
5937 KiB  
Guidelines
Treatment of Acute Respiratory Failure in the Course of COVID-19. Practical Hints from the Expert Panel of the Assembly of Intensive Care and Rehabilitation of the Polish Respiratory Society
by Malgorzata Czajkowska-Malinowska, Aleksander Kania, Paweł Kuca, Jacek Nasiłowski, Szymon Skoczyński, Rafał Sokołowski and Paweł Śliwiński
Adv. Respir. Med. 2020, 88(3), 245-266; https://doi.org/10.5603/ARM.2020.0109 - 18 Jul 2020
Cited by 10 | Viewed by 684
Abstract
In 2019, a pandemic began due to infection with a novel coronavirus, SARS-CoV-2. In many cases, this coronavirus leads to the development of the COVID-19 disease. Lung damage in the course of this disease often leads to acute hypoxic respiratory failure and may [...] Read more.
In 2019, a pandemic began due to infection with a novel coronavirus, SARS-CoV-2. In many cases, this coronavirus leads to the development of the COVID-19 disease. Lung damage in the course of this disease often leads to acute hypoxic respiratory failure and may eventually lead to acute respiratory distress syndrome (ARDS). Respiratory failure as a result of COVID-19 can develop very quickly and a small percent of those infected will die because of it. There is currently no treatment for COVID-19, therefore the key therapeutic intervention centers around the symptomatic treatment of respiratory failure. The main therapeutic goal is to main-tain gas exchange, mainly oxygenation, at an appropriate level and prevent the intensification of changes in the lung parenchyma. Depending on the severity of hypoxemia different techniques can be used to improve oxygenation. Medical staff dealing with COVID-19 patients should be familiar with both, methods used to treat respiratory failure and the epidemiological risks arising from their use. In some patients, conventional (passive) oxygen therapy alone is sufficient. In patients with worsening respiratory failure high flow nasal oxygen therapy (HFNOT) may be effective. The continuous positive airway pressure (CPAP) and non-invasive ventilation (NIV) methods can be used to a limited extent. With further disease progression, invasive ventilation must be used and in special situations, extracorporeal membrane oxygenation (ECMO) can also be administered. The authors of this article set themselves the goal of presenting the most current knowledge about the epidemiology and patho-physiology of respiratory failure in COVID-19, as well as the methods of its treatment. Given the dynamics of the developing pandemic, this is not an easy task as new scientific data is presented almost every day. However, we believe the knowledge contained in this study will help doctors care for patients with COVID-19. The main target audience of this study is not so much pneumonologists or intensivists who have extensive experience in the application of the techniques discussed here, but rather doctors of other specializations who must master new skills in order to help patients during the time of a pandemic. Full article
373 KiB  
Review
Non-Invasive Ventilation in Patients with an Altered Level of Consciousness. A Clinical Review and Practical Insights
by Gil Gonçalves, Haitham Saeed, Mohamed E. Abdelrahim, Hadeer S. Harb, Yasmin M. Madney, Kevin Eng, Habib MR Karim, Mohamad El-Khatib, Bushra Mina, Szymon Skoczyński, Irena Sarc, Vânia Caldeira, Sara M. Cabral, Bruno Cabrita, Miguel Guia, Jun Duan, Igor Barjaktarevic, Giuseppe Fiorentino, Edoardo Piervincenzi, Güniz Köksal, Sibel O. Sarin, Peter J. Papadakos, Benan Bayrakci, Vijay Hadda, Gerhard Laier-Groeneveld, Karen EA Burns, Raffaele Scala, Andres C. Alcaraz and Antonio M Esquinasadd Show full author list remove Hide full author list
Adv. Respir. Med. 2020, 88(3), 233-244; https://doi.org/10.5603/ARM.2020.0110 - 18 Jul 2020
Cited by 5 | Viewed by 874
Abstract
Non-invasive ventilation has gained an increasingly pivotal role in the treatment of acute hypoxemic and/or hypercapnic respira-tory failure and offers multiple advantages over invasive mechanical ventilation. Some of these advantages include the preserva-tion of airway defense mechanisms, a reduced need for sedation, and [...] Read more.
Non-invasive ventilation has gained an increasingly pivotal role in the treatment of acute hypoxemic and/or hypercapnic respira-tory failure and offers multiple advantages over invasive mechanical ventilation. Some of these advantages include the preserva-tion of airway defense mechanisms, a reduced need for sedation, and an avoidance of complications related to endotracheal intubation. Despite its advantages, non-invasive ventilation has some contraindications that include, among them, severe encephalopathy. In this review article, the rationale, evidence, and drawbacks of the use of noninvasive ventilation in the context of hypercapnic and non-hypercapnic patients with an altered level of consciousness are analyzed. Full article
288 KiB  
Review
Effective Components of Self-Management Programs for Chronic Obstructive Pulmonary Disease Patients: Scoping Review
by Rita Georges Nohra, Rola Bou Serhal, Hala Sacre, Pascale Salameh and Monique Rothan-Tondeur
Adv. Respir. Med. 2020, 88(3), 223-232; https://doi.org/10.5603/ARM.2020.0117 - 18 Jul 2020
Cited by 4 | Viewed by 821
Abstract
Introduction: To date, little guidance is available to support the development of effective programs for improving self-management in chronic obstructive pulmonary disease (COPD) patients. Yet, given the global burden of this disease, it seems important to identify the components of a self-management program [...] Read more.
Introduction: To date, little guidance is available to support the development of effective programs for improving self-management in chronic obstructive pulmonary disease (COPD) patients. Yet, given the global burden of this disease, it seems important to identify the components of a self-management program that are effective in terms of health outcomes for COPD patients. Objectives: This review aims to identify effective elements of a self-management program for COPD patients, the ones that may impact quality of life, emergency visits, and rehospitalization rates. Material and methods: A systematic literature search of three databases (Medline, Cochrane, and CINHAL) was conducted to identify studies on self-management of COPD, with three limiting parameters: published in twelve years prior to November 2019, in English or French, and including patients over 40 years old. Prisma was used to guide the work process. Results: The search yielded 361 studies from the three electronic databases by applying limiting criteria, and after removing duplicates. Sixty-five articles were identified as relevant based on their titles and abstracts. However, 16 documents were retained after full reading. The analysis of the included articles identified 4 components in self-management programs for COPD patients: initiation stage of the intervention, educational sessions, support and monitoring methods. Conclusions: Although the combination of self-management program initiation, educational sessions, support and monitoring methods were effective, further research is needed to identify the components that have better impact on COPD patients’ skills and quality of life. Full article
310 KiB  
Article
Chronic Obstructive Pulmonary Disease is Associated with a Higher Level of Serum Uric Acid. A Systematic Review and Meta-Analysis
by Phuuwadith Wattanachayakul, Pongprueth Rujirachun, Nipith Charoenngam and Patompong Ungprasert
Adv. Respir. Med. 2020, 88(3), 215-222; https://doi.org/10.5603/ARM.2020.0119 - 18 Jul 2020
Cited by 9 | Viewed by 642
Abstract
Introduction: Recent studies have suggested that patients with chronic obstructive pulmonary disease (COPD) may have a higher level of serum uric acid compared with individuals without COPD, although the data are still limited. The current systematic review and meta-analysis was conducted to summarize [...] Read more.
Introduction: Recent studies have suggested that patients with chronic obstructive pulmonary disease (COPD) may have a higher level of serum uric acid compared with individuals without COPD, although the data are still limited. The current systematic review and meta-analysis was conducted to summarize all available data. Material and methods: A systematic review was performed using the MEDLINE and EMBASE databases from their inception to July 2019. Studies that were eligible for the meta-analysis must have consisted of two groups of participants, patients with COPD and individuals without COPD. The eligible studies must have reported either mean or median level of serum uric acid and its standard deviation (SD) or interquartile range of participants in both groups. Mean serum uric acid level and SD of participants in both groups were extracted from each study and the mean difference (MD) was calculated. Pooled MD was then computed by combining MDs of each study using random effects model. Results: A total of eight studies with 1,612 participants met the eligibility criteria and were included in the data analysis. The serum uric acid level among patients with COPD was significantly higher than individuals without COPD with the pooled MD of 0.91 mg/dL (95% CI: 0.45–1.38; I2 = 89%). Conclusions: The current study found a significantly higher level of serum uric acid among patients with COPD than individuals without COPD. Full article
526 KiB  
Article
Analysis of the Incidence of Acute Respiratory Diseases in the Paediatric Population in Poland in the Light of the “Health Needs Map”
by Joanna Lange, Jerzy Kozielski, Kinga Bartolik, Paweł Kabicz and Tomasz Targowski
Adv. Respir. Med. 2020, 88(3), 204-214; https://doi.org/10.5603/ARM.2020.0106 - 18 Jul 2020
Cited by 3 | Viewed by 475
Abstract
Introduction: Statistical data on the structure of acute respiratory diseases incidence in the paediatric population are still scarce. The demand for such data results mainly from the need to constantly implement new systemic and economic solutions. The aim of the study was to [...] Read more.
Introduction: Statistical data on the structure of acute respiratory diseases incidence in the paediatric population are still scarce. The demand for such data results mainly from the need to constantly implement new systemic and economic solutions. The aim of the study was to attempt to use reported data for an assessment of the incidence of acute respiratory diseases in various age groups. Material and methods: An analysis of selected acute respiratory diseases was conducted in relation to diagnoses reported from 1 January to 31 December 2014 to the National Health Fund (NFZ, Narodowy Fundusz Zdrowia) in accordance with the codes of the International Statistical Classification of Diseases and Related Health Problems, 10th Revision. The study was conducted under the Knowledge Education Development operational programme co-funded by the European Social Fund. Results: A total of 101,000 children were hospitalised due to acute respiratory diseases, which amounted to 1,554 hospitalisa-tions per 100.000. The most common causes of hospitalisation were pneumonia and bronchitis/bronchiolitis. Boys were hospital-ised more often in each age group. The shortest average length of stay (ALOS) was 5.21 days and concerned hospitalisation due to bronchitis. The longest length of stay for children was due to tuberculosis (14.3 days). The highest age average of a child was recorded in pleural diseases (10.51 years) and the lowest in bronchitis (2.93 years). Rehospitalisation was necessary in children in whom tuberculosis or pleural diseases were diagnosed (1.43 vs 1.34). A total of 67 inpatient deaths were recorded, of which 19 were due to pneumonia or its complications. Conclusions: Epidemiological data reported to the National Health Fund (NFZ) seem quite reliable and do not differ significantly from those reported in other European countries. The analysed data may be useful in estimating health needs in paediatrics. Full article
569 KiB  
Article
Severe and Fatal Measles-Associated Pneumonia during an Outbreak in Italy: Data from the Heart of the Epidemic
by Daniele Lombardo, Giovanni Ciampi and Lucia Spicuzza
Adv. Respir. Med. 2020, 88(3), 197-203; https://doi.org/10.5603/ARM.2020.0118 - 18 Jul 2020
Cited by 3 | Viewed by 469
Abstract
Introduction: Measles is a contagious disease that re-emerged among young adults as a consequence of suboptimal vaccination coverage. Since in the pre-vaccination era measles affected mainly children, little is known about measles-associated respiratory complications in adults. The aim of this study was to [...] Read more.
Introduction: Measles is a contagious disease that re-emerged among young adults as a consequence of suboptimal vaccination coverage. Since in the pre-vaccination era measles affected mainly children, little is known about measles-associated respiratory complications in adults. The aim of this study was to describe clinical and radiological findings in adults affected by measles who developed respiratory complications during a recent measles outbreak. Material and methods: In this retrospective chart review-based study we analyzed data from patients admitted for measles from January to June 2018 to a large tertiary care hospital, in one of the main cities in the south of Italy. This city has been the country’s heart of the epidemic with a high morbidity and mortality rate. Results: Among 177 patients (mean age 26 ± 9 years), only 2 were vaccinated. Thirty patients (16.9%) had signs of pneumonia on chest radiography. Computed tomography scan showed the following abnormalities: centrilobular nodules (63%), ground-glass attenuation (63%), air-space consolidation (36%), pleural effusion (16%) and pneumothorax (10%). Five patients developed severe lung injury and hypoxemia requiring admission to Intensive Care Unit. Two young unvaccinated women with no past medical history died from acute respiratory failure. The death was sudden and unpredictable. Conclusions: Measles-associated pneumonia in unvaccinated young adults can cause severe respiratory impairment and death. Our findings support the need for a mandatory vaccination policy. Full article
279 KiB  
Article
Effectiveness of Osimertinib in Patients with Lung Adenocarcinoma in Clinical Practice—The Expanded Drug Access Program in Poland
by Magdalena Knetki-Wróblewska, Dariusz M. Kowalski, Grzegorz Czyżewicz, Maciej Bryl, Anna Wrona, Rafał Dziadziuszko, Robert Kieszko, Janusz Milanowski, Daria Świniuch, Rodryg Ramlau, Ewa Chmielowska and Maciej Krzakowski
Adv. Respir. Med. 2020, 88(3), 189-196; https://doi.org/10.5603/ARM.2020.0130 - 18 Jul 2020
Cited by 2 | Viewed by 642
Abstract
Introduction: Osimertinib is a third-generation, irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that has demonstrated efficacy in the treatment of EGFR-mutant non-small-cell lung cancer (NSCLC) in prospective clinical trials. Material and methods: This retrospective analysis evaluated the outcomes of 32 pretreated [...] Read more.
Introduction: Osimertinib is a third-generation, irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that has demonstrated efficacy in the treatment of EGFR-mutant non-small-cell lung cancer (NSCLC) in prospective clinical trials. Material and methods: This retrospective analysis evaluated the outcomes of 32 pretreated patients with EGFR T790M mutation who received osimertinib in clinical practice at seven centers in Poland within the Expanded Drug Access Program. Osimertinib was used in the second line in 59% of patients and in later lines in 41%. Results: Objective response was attained in 16 patients (50%), and 12 subjects (38%) had stable disease. Median progression -free survival was 11.3 months in the overall population, 12.6 months in patients with EGFR exon 19 mutation and 7.5 months in patients with EGFR exon 21 mutation (p = 0.045). Median overall survival (OS) was 18.3 months. Overall, 58.4% and 45.6% of patients remained in follow-up after 12 and 24 months, respectively. Median OS appeared longer for patients without cerebral metastases than for those with cerebral metastases (27.4 vs. 9.4 months, respectively; p = 0.078), and for patients with the Eastern Cooperative Oncology Group performance status (ECOG PS) 0–1 than those with ECOG PS 2 (27.4 vs. 11.8 months, respectively; p = 0.189), although neither result reached statistical significance. Median OS of patients with partial response, stable disease and progressive disease was 27.4, 12.7 and 4.5 months, respectively (p < 0.001). Age, comorbidities, line of treatment with osimertinib, and type of activating EGFR mutation did not impact on OS. Adverse events of any grade or grade 3/4 were reported in 38% and 9% of patients, respectively. One person discontinued due to interstitial pneumonia. Conclusion: These results confirm the value of osimertinib in patients with previously treated EGFR T790M-mutant NSCLC. Clinical benefit was evident in patients with cerebral metastases and moderate performance status. Full article
181 KiB  
Article
The Role of Genexpert in the Diagnosis of Mycobacterium tuberculosis
by Chinnu Sasikumar, Ketaki Utpat, Unnati Desai and Jyotsna Joshi
Adv. Respir. Med. 2020, 88(3), 183-188; https://doi.org/10.5603/ARM.2020.0102 - 18 Jul 2020
Cited by 9 | Viewed by 626
Abstract
Introduction: GeneXpert (GX) is a novel, integrated, cartridge-based, nucleic acid amplification test with an established role for rapid diagnosis of Mycobacterium tuberculosis and detection of rifampicin resistance. Aim: To evaluate the role of GX in pulmonary and extrapulmonary tuberculosis (TB) cases. Material and [...] Read more.
Introduction: GeneXpert (GX) is a novel, integrated, cartridge-based, nucleic acid amplification test with an established role for rapid diagnosis of Mycobacterium tuberculosis and detection of rifampicin resistance. Aim: To evaluate the role of GX in pulmonary and extrapulmonary tuberculosis (TB) cases. Material and methods: A prospective study was conducted in the pulmonary medicine department of a tertiary care hospital after the Ethics Comittee permission. Data of 257 presumptive TB patients was retrieved for GX, acid fast bacilli smear and cul-ture (AFB smear and culture) and drug susceptibility test (DST). Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) of GX in diagnosis and determination of rifampicin resistance in pulmonary and extrapulmonary TB cases were calculated and compared with culture and DST results. Results: Our study included 132 pulmonary and 125 extrapulmonary cases. On the basis of clinicoradiological and microbiological correlation, diagnosis of TB was confirmed in 104 pulmonary and 103 extrapulmonary cases. Out of a total of 104 pulmonary TB cases, 73 were rifampicin-sensitive and 31 were rifampicin-resistant cases. 103 extrapulmonary TB patients included 66 rifampicin-sensitive and 37 rifampicin-resistant cases. The sensitivity, specificity, PPV, NPV of GX in diagnosis and detection of rifampicin resistance in pulmonary TB was 95%, 93%, 98%, 84% and 96%, 100%, 100%, 96%, respectively. The sensitivity, specificity, PPV, NPV of GX in diagnosis and detection of rifampicin resistance in extrapulmonary TB cases was 79%, 86%, 96%, 47% and 97%, 95%, 97%, 95%, respectively. Conclusions: GX results are superior to smear microscopy and comparable to culture with shorter turnaround time.We recom-mend using it in routine TB diagnosis as this will expedite the management of patients with presumptive TB. Full article
339 KiB  
Article
A Study on the Effect of Intraoperative Continuous Positive Airway Pressure (CPAP) on the Postoperative Pulmonary Function in Overweight Patients Undergoing Lower Limb, Lower Abdominal or Vaginal Surgeries under Spinal Anesthesia
by Mamatha Munaf, Chitra Rajeswari, Rajaram Manju and Hemavathi Balachander
Adv. Respir. Med. 2020, 88(3), 176-182; https://doi.org/10.5603/ARM.2020.0105 - 18 Jul 2020
Cited by 2 | Viewed by 477
Abstract
Introduction: Spinal anaesthesia, supine position and higher BMI are risk factors for pulmonary atelectasis. NIV, PEEP and CPAP are employed in ICU’s to treat atelectasis postoperatively. However, we wanted to investigate whether CPAP was protective against atelectasis when used intraoperatively, in high risk [...] Read more.
Introduction: Spinal anaesthesia, supine position and higher BMI are risk factors for pulmonary atelectasis. NIV, PEEP and CPAP are employed in ICU’s to treat atelectasis postoperatively. However, we wanted to investigate whether CPAP was protective against atelectasis when used intraoperatively, in high risk patients. Material and methods: This study was a randomized controlled trial. Overweight patients, who were to undergo surgeries under spinal anesthesia were included in the study. After informed consent, 126 patients underwent preoperative pulmonary function tests (PFT: FEV1, FVC, PEFR). Following the onset of spinal anaesthesia patients were randomised into group E (n = 63, received CPAP) and control group, group C ( n =63, received nil intervention). Postoperative PFT was done at 20 minutes, 1 hour, 2 hours and 3 hours after surgery. Patients were followed up till discharge for pulmonary complications. Results: We observed significant reduction in pulmonary function (FEV1, FVC and PEFR) postoperatively compared to base-line. CPAP group had better pulmonary function when compared to control group, the difference being significant 20 minu-tes after the surgery (p < 0.05). No postoperative pulmonary complication was reported among the 126 patients studied. Conclusion: Intraoperative use of CPAP in overweight patients undergoing surgeries under spinal anaesthesia could be beneficial in improving pulmonary function in the immediate post-operative period. Full article
139 KiB  
Letter
Relative Lymphocytosis in COVID-19—A Ray of Hope
by Pranav Ish, Nipun Malhotra, Sumita Agrawal and Nitesh Gupta
Adv. Respir. Med. 2020, 88(3), 287-288; https://doi.org/10.5603/ARM.a2020.0098 - 09 Jun 2020
Cited by 6 | Viewed by 430
Abstract
A recent article on 150 COVID-19 patients from Wuhan, China, was a comprehensive analysis of clinical predictors of mortality [...] Full article
105 KiB  
Letter
The Catch-22 of the COVID-19 “Lockdown”
by Nipun Malhotra and Shekhar Kunal
Adv. Respir. Med. 2020, 88(3), 285-286; https://doi.org/10.5603/ARM.a2020.0097 - 09 Jun 2020
Cited by 3 | Viewed by 345
Abstract
The turn of the year marked the ominous birth of what later developed into a pandemic [...] Full article
128 KiB  
Editorial
Stopping the SARS-CoV-2 Surge in the USA-CDC Recommendations and Ground Realities
by Harpreet Singh and Tarun Popli
Adv. Respir. Med. 2020, 88(3), 173-175; https://doi.org/10.5603/ARM.a2020.0099 - 09 Jun 2020
Cited by 4 | Viewed by 418
Abstract
As of May 10, 2020, the United States of America (USA) has 1,367,079 cases of SARS-CoV-2 and 80,773 deaths associated with the disease [...] Full article
Previous Issue
Next Issue
Back to TopTop